Statistics

Total Visits

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors39

Select a period of time:

Number of views in the range

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors25

Views

Views
November 20242
December 20240
January 20252
February 20253
March 202515
April 20253
May 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States5
United Kingdom3
Spain1
Hong Kong1
 

Top cities views

Views
Buffalo2
Council Bluffs1
Hong Kong1
London1